• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form S-1/A filed by Envoy Medical Inc.

    2/9/26 9:55:56 PM ET
    $COCH
    Industrial Specialties
    Health Care
    Get the next $COCH alert in real time by email
    S-1/A 1 ea0276207-s1a2_envoy.htm AMENDMENT NO. 2 TO FORM S-1

    As filed with the U.S. Securities and Exchange Commission on February 9, 2026

    Registration No. 333-292260

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    AMENDMENT NO. 2

    TO

    FORM S-1
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933

     

    Envoy Medical, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   3842   86-1369123
    (State or other jurisdiction of
    incorporation or organization)
      (Primary Standard Industrial
    Classification Code Number)
      (IRS Employer
    Identification Number)

     

    4875 White Bear Parkway

    White Bear Lake, MN 55110

    Tel: (877) 900-3277

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    Brent T. Lucas

    Chief Executive Officer

    Envoy Medical, Inc.

    4875 White Bear Parkway

    White Bear Lake, MN 55110

    Tel: (877) 900-3277
    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    With copies to:

     

    Andrew M Nick, Esq. Steven M. Skolnick, Esq.
    Fredrikson & Byron, P.A. Lowenstein Sandler LLP
    60 South Sixth Street; Suite 1500 1251 Avenue of the Americas
    Minneapolis, MN 55402 New York, New York 10020
    (612) 492-7000 (212) 262-6700

     

    Approximate date of commencement of proposed sale to the public: From time to time after this Registration Statement becomes effective.

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 (the “Securities Act”) check the following box: ☒

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
        Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

    The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    Envoy Medical, Inc. is filing this Amendment No. 2 to its Registration Statement on Form S-1, as amended (File No. 333-292260), as an exhibits-only filing. Accordingly, this amendment consists only of the facing page, this explanatory note, Item 16(a) of Part II of the Registration Statement, the signature page to the Registration Statement and the filed exhibits. The remainder of the Registration Statement is unchanged and has been omitted.

     

    1

     

     

    PART II 

     

    INFORMATION NOT REQUIRED IN PROSPECTUS

     

    Item 16.  Exhibits.

     

            Incorporated by Reference
    Exhibit
    Number
      Description   Schedule/
    Form
      File No.   Exhibit   Filing Date
    3.1     Second Amended and Restated Certificate of Incorporation of the Company.   8-K   001-40133   3.1   October 5, 2023
    3.2     Amended and Restated Bylaws of the Company.   8-K   001-40133   3.2   October 5, 2023
    3.3     Certificate of Designation of Series A Preferred Stock of the Company.   8-K   001-40133   3.3   October 5, 2023
    4.1     Warrant Agreement, dated March 1, 2021, between Anzu Special Acquisition Corp I and Equiniti Trust Company, LLC (formerly known as American Stock Transfer & Trust Company, LLC), as Warrant Agent.   8-K   001-40133   10.1   March 4, 2021
    4.2     Form of Shortfall Warrant.   S-1/A   333-276590   4.2   February 15, 2024
    4.3   Description of Securities.   10-K    001-40133   4.3    April 1, 2024 
    4.4   Form of Private Warrant.   10-K    001-40133   4.4   March 31, 2025
    4.5   Form of September Private Placement Warrant   8-K   001-40133   4.1   September 23, 2025
    4.6   Form of September Placement Agent Warrant   8-K   001-40133   4.2   September 23, 2025
    4.7   Form of October Private Placement Warrant   8-K   001-40133   4.1   October 9, 2025
    4.8   Form of October Placement Agent Warrant   8-K   001-40133   4.2   October 9, 2025
    4.9 (**)   Form of Pre-Funded Warrant to be issued in this offering   S-1   333-292260   4.9   February 6, 2026
    4.10 (**)   Form of Series A-1 Warrant to be issued in this offering   S-1   333-292260   4.10   February 6, 2026
    4.11 (**)   Form of Series A-2 Warrant to be issued in this offering   S-1   333-292260   4.11   February 6, 2026
    4.12 (**)   Form of Placement Agent Warrant to be issued in this offering   S-1   333-292260   4.12   February 6, 2026
    5.1 (**)   Opinion of Fredrikson & Byon, P.A.   S-1   333-292260   5.1   February 6, 2026
    10.1     Amendment to Letter Agreement, dated September 29, 2023, by and among Anzu Special Acquisition Corp I, Anzu SPAC GP I LLC and Anzu’s officers and directors.   8-K   001-40133   10.2   October 5, 2023
    10.2 (+)     Amended and Restated Registration Rights Agreement, dated September 29, 2023, by and among Anzu Special Acquisition Corp I, Anzu SPAC GP I LLC and certain stockholders.   8-K   001-40133   10.3   October 5, 2023
    10.3 (*)     Envoy Medical, Inc. Equity Incentive Plan.   8-K   001-40133   10.22   October 5, 2023
    10.4 (*)     Envoy Medical, Inc. Employee Stock Purchase Plan.   8-K   001-40133   10.23   October 5, 2023
    10.5 (*)     Form of Envoy Medical, Inc. Indemnification Agreement.   8-K   001-40133   10.21   October 5, 2023
    10.6     Forward Purchase Agreement, dated as of April 17, 2023.   8-K   001-40133   10.4   April 18, 2023
    10.7 (+)     Amendment No. 1 to Forward Purchase Agreement, dated as of May 25, 2023.   S-4/A   333-271920   10.27   June 30, 2023
    10.8     Amendment No. 2 to Forward Purchase Agreement, dated as of September 28, 2023.   8-K   001-40133   10.24   October 5, 2023
    10.9 (*)     Employment Agreement, dated October 16, 2023, between Envoy Medical Corporation and Brent T. Lucas.   8-K   001-40133   10.1   October 20, 2023
    10.10 (*)     Employment Agreement, dated August 15, 2023, between Envoy Medical Corporation and David R. Wells.   10-Q   001-40133   10.10   November 17, 2023
    10.11 (*)     Letter Agreement, dated February 14, 2024, between Envoy Medical Corporation and Charles R. Brynelsen.   10-K   001-40133   10.11    April 1, 2024 
    10.12 (*)     Letter Agreement, dated February 14, 2024, between Envoy Medical Corporation and Susan Kantor.   10-K    001-40133   10.12    April 1, 2024 
    10.13 (*)     Letter Agreement, dated February 14, 2024, between Envoy Medical Corporation and Mona Patel.   10-K   001-40133   10.13    April 1, 2024 

     

    II-1

     

     

    10.14 (*)     Letter Agreement, dated February 14, 2024, between Envoy Medical Corporation and Janis Smith-Gomez.   10-K   001-40133   10.14    April 1, 2024 
    10.15 (*)     Form of Option Award Agreement.   10-K   001-40133   10.15    April 1, 2024 
    10.16   Promissory Note, dated February 27, 2024, between Envoy Medical, Inc. and GAT Funding, LLC   10-Q   001-40133   10.1   May 15, 2024
    10.17   Amendment to Forward Stock Purchase Agreement, dated July 29, 2024, between Envoy Medical, Inc. and the Meteroa FPA Parties.   8-K   001-40133   10.1   August 1, 2024
    10.18   Promissory Note, dated August 27, 2024, between Envoy Medical, Inc. and GAT Funding, LLC.   10-Q   001-40133   10.1   November 14, 2024
    10.19   Conversion and Waiver Agreement, dated December 20, 2024, by and between Envoy Medical, Inc. and Anzu SPAC GP I LLC.   8-K   001-40133   10.1   December 20, 2024
    10.20   Amendment No. 1 to Common Stock Purchase Warrant, issued by Envoy Medical, Inc. to the Meteora Parties.   8-K   001-40133   10.1   June 25, 2024
    10.21   Amendment No. 2 to Common Stock Purchase Warrant, issued by Envoy Medical, Inc. to the Meteora Parties.   8-K   001-40133   10.1   December 23, 2024
    10.22   At The Market Offering Agreement dated as of January 17, 2025, between Envoy Medical, Inc and Roth Capital Partners, LLC   8-K   001-40133   10.1   January 21, 2025
    10.23   Building Lease dated as of May 20, 2016, between Envoy Medical Corporation and Taylor Corporation, as amended.   10-K    001-40133   10.23   March 31, 2025
    10.24   Servies Agreement dated as of January 1, 2022, between Envoy Medical Corporation and Taylor Technology Services, Inc.   10-K    001-40133   10.24   March 31, 2025
    10.25   Promissory Note, dated March 6, 2025, between Envoy Medical, Inc. and GAT Funding, LLC.    10-Q   001-40133   10.2   May 1, 2025
    10.26   Amended and Restated Envoy Medical, Inc. 2023 Equity Incentive Plan   8-K   001-40133   10.1   June 3, 2025
    10.27   Consulting Agreement by and between the Company and Oasis Business Consulting, LLC, dated effective June 23, 2025.   8-K   001-40133   10.1   June 25, 2025
    10.28   Satisfaction of Promissory Notes by and between the Company and GAT Funding, LLC, dated effective August 25, 2025.   8-K   001-40133   10.1   August 26, 2025
    10.29   Amendment to Forward Stock Purchase Agreement, between the Meteora FPA Parties and the Company, dated July 28, 2025.    8-K   001-40133   10.1   July 29, 2025
    10.30   Warrant Extension and Voting Agreement, by and among the Company, GAT Funding, LLC, Taylor Sports Group, Inc., and Glen A. Taylor, dated September 4, 2025.   8-K   001-40133   10.1   September 9, 2025
    10.31   Form of September Purchase Agreement   8-K   001-40133   10.1   September 23, 2025
    10.32   Form of October Purchase Agreement   8-K   001-40133   10.1   October 9, 2025
    10.33(**)   Form of Securities Purchase Agreement to be entered into in connection with this offering   S-1   333-292260   10.33   February 6, 2026
    10.34(#)   Engagement Letter, dated September 17, 2025, by and between Envoy Medical, Inc. and H.C. Wainwright & Co., LLC, as amended on December 17, 2025 and February 9, 2026.   -   -   -   -
    21.1   List of Subsidiaries.   10-K    001-40133   21.1   March 31, 2025
    23.1(**)   Consent of Grant Thornton LLP.   S-1   333-292260   23.1   February 6, 2026
    23.2(**)   Consent of Fredrikson & Byron, P.A. (included as part of Exhibit 5.1).   S-1   333-292260   5.1   February 6, 2026
    24.1(**)   Power of Attorney (included on signature page to this Registration Statement).   S-1   333-292260       February 6, 2026
    107(**)   Filing Fee Table   S-1   333-292260   107   February 6, 2026

     

    (*) Indicates a management contract or compensatory plan.
       
    (**) Previously filed

     

    (#) Filed herewith.

     

    (+) Certain schedules and exhibits to this Exhibit have been omitted pursuant to Item 601(a)(5) or Item 601(b)(10)(iv), as applicable, of Regulation S-K The Registrant agrees to furnish supplemental copies of all omitted exhibits and schedules to the Securities and Exchange Commission upon its request.

     

    II-2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of White Bear Lake, State of Minnesota on February 9, 2026.

     

      ENVOY MEDICAL, INC.
         
      /s/ Brent T. Lucas
      Name: Brent T. Lucas
      Title: Chief Executive Officer

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the date indicated.

     

    Signature   Title   Date
             
    /s/ Brent T. Lucas   Chief Executive Officer and Director   February 9, 2026
    Brent T. Lucas   (Principal Executive Officer)    
             
    *   Interim Chief Financial Officer   February 9, 2026
    Robert Potashnick   (Principal Financial and Accounting Officer)    
             
    *   Director   February 9, 2026
    Charles R. Brynelsen        
             
    *   Director   February 9, 2026
    Michael Crowe        
             
    *   Director   February 9, 2026
    Mona Patel        
             
    *   Director   February 9, 2026
    Janis Smith-Gomez        
             
    *   Director   February 9, 2026
    Susan J. Kantor        

     

    *By: /s/ Brent T. Lucas   Date: February 9, 2026
    Name: Brent T. Lucas    
    Title: Attorney-in-Fact    

     

    II-3

     

    Get the next $COCH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COCH

    DatePrice TargetRatingAnalyst
    6/24/2024$8.50Buy
    Ascendiant Capital Markets
    More analyst ratings

    $COCH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Interim CFO Potashnick Robert

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/9/26 5:45:38 PM ET
    $COCH
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Chief Executive Officer Lucas Brent T.

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/9/26 5:45:09 PM ET
    $COCH
    Industrial Specialties
    Health Care

    Chief Executive Officer Lucas Brent T. was granted 18,105 shares, increasing direct ownership by 8% to 234,590 units (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    12/10/25 5:49:36 PM ET
    $COCH
    Industrial Specialties
    Health Care

    $COCH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ascendiant Capital Markets initiated coverage on Envoy Medical with a new price target

    Ascendiant Capital Markets initiated coverage of Envoy Medical with a rating of Buy and set a new price target of $8.50

    6/24/24 7:29:10 AM ET
    $COCH
    Industrial Specialties
    Health Care

    $COCH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Small Cap Growth Virtual Investor Conference: Presentations Now Available for On-Demand Viewing

    NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Small Cap Growth Virtual Investor Conference, held February 5th are now available for on-demand viewing. Individual investors, institutional investors, advisors, and analysts are invited to attend.REGISTER AND VIEW PRESENTATIONS HERE The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company's resource section. Select companies are accepting 1x1 management meeting requests through February 10th. Please Schedule 1x1 Meetings here Febru

    2/6/26 8:35:00 AM ET
    $ADGM
    $COCH
    Medical/Dental Instruments
    Health Care
    Industrial Specialties

    Small Cap Growth Virtual Investor Conference Agenda Announced for February 5th

    NEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, announced the agenda for the Small Cap Growth Virtual Investor Conference to be held February 5th. Individual investors, institutional investors, advisors, and analysts are invited to attend.REGISTER HERE It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations, or schedule 1x1 meetings with management. Please Schedule 1x1 Meetings Here "We are proud to highlight this diverse roster of companies that demonstrate the innovation taking pl

    2/2/26 8:35:00 AM ET
    $ADGM
    $COCH
    Medical/Dental Instruments
    Health Care
    Industrial Specialties

    Envoy Medical to Present at the Small Cap Growth Virtual Investor Conference February 5

    WHITE BEAR LAKE, Minn., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that management will participate in the Small Cap Growth Virtual Investor Conference on February 5, 2026. Small Cap Growth Virtual Investor Conference Presentation Details:Date: Thursday, February 5, 2026Time: 10:00 A.M. ETREGISTER HERE A question-and-answer session will follow the presentation, during which investors may submit questions in real time. If attendees are not able to join the live event, a link to the recording will be available on Envoy's Investor Relations webs

    1/29/26 8:35:00 AM ET
    $COCH
    Industrial Specialties
    Health Care

    $COCH
    SEC Filings

    View All

    Amendment: SEC Form S-1/A filed by Envoy Medical Inc.

    S-1/A - Envoy Medical, Inc. (0001840877) (Filer)

    2/9/26 9:55:56 PM ET
    $COCH
    Industrial Specialties
    Health Care

    Amendment: SEC Form S-1/A filed by Envoy Medical Inc.

    S-1/A - Envoy Medical, Inc. (0001840877) (Filer)

    2/6/26 10:58:13 AM ET
    $COCH
    Industrial Specialties
    Health Care

    SEC Form EFFECT filed by Envoy Medical Inc.

    EFFECT - Envoy Medical, Inc. (0001840877) (Filer)

    12/31/25 12:15:09 AM ET
    $COCH
    Industrial Specialties
    Health Care

    $COCH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Patel Mona Chetan bought $3,675 worth of shares (2,500 units at $1.47), increasing direct ownership by 14% to 20,000 units (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    6/13/25 4:10:30 PM ET
    $COCH
    Industrial Specialties
    Health Care

    Director Patel Mona Chetan bought $14,600 worth of shares (10,000 units at $1.46), increasing direct ownership by 133% to 17,500 units (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    6/10/25 4:11:23 PM ET
    $COCH
    Industrial Specialties
    Health Care

    Director Brynelsen Charles bought $82,403 worth of shares (50,000 units at $1.65) (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    5/27/25 6:34:31 PM ET
    $COCH
    Industrial Specialties
    Health Care

    $COCH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Envoy Medical Inc.

    SC 13G - Envoy Medical, Inc. (0001840877) (Subject)

    11/14/24 8:49:34 AM ET
    $COCH
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by Envoy Medical Inc.

    SC 13G - Envoy Medical, Inc. (0001840877) (Subject)

    11/13/24 4:40:10 PM ET
    $COCH
    Industrial Specialties
    Health Care

    $COCH
    Leadership Updates

    Live Leadership Updates

    View All

    Envoy Medical Extinguishes over $32 Million in Debt, Strengthening Balance Sheet; Announces Retirement of Glen A. Taylor from Board

    Extinguishment simplifies capital structure, strengthens foundation for growth, and eliminates all term loan obligations, without equity conversionWhite Bear Lake, Minnesota--(Newsfile Corp. - August 26, 2025) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced it has satisfied and extinguished the outstanding term loans from GAT Funding, LLC, which totaled $32 million in outstanding principal and accrued interest, in exchange for a payment of $100,000 in cash. GAT Funding is owned by Glen A. Taylor, who also announced his retirement from the Envoy Medical board after two decades of ser

    8/26/25 8:00:00 AM ET
    $COCH
    Industrial Specialties
    Health Care

    Envoy Medical Announces Addition of Medical Device Manufacturing Experience to its Board of Directors to Prepare for Scaling

    WHITE BEAR LAKE, Minn., June 11, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ:COCH) today announced the appointment of Michael Crowe to the Envoy Medical Board of Directors effective June 7, 2024. Envoy Medical is currently sponsoring an Early Feasibility Study at Mayo Clinic in Rochester, Minnesota for its investigational fully implanted Acclaim® Cochlear Implant. Envoy Medical expects to begin a larger pivotal clinical study for its device later in 2024. Mr. Crowe, who received his BS in Electrical Engineering from the University of Louisville and his MBA from Duke University, has decades of experience helping companies grow operations quickly and efficiently

    6/11/24 8:00:00 AM ET
    $COCH
    Industrial Specialties
    Health Care

    Envoy Medical to Host Fireside Chat Event December 7

    Analyst Hosted Event to Feature Comprehensive Discussion of Envoy Medical's Products, Interviews with Two Study Investigators and Key Opinion Leaders in Cochlear Implants WHITE BEAR LAKE, Minnesota, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ: "COCH"), a revolutionary hearing health company focused on fully implanted hearing systems, today announced that it will host a fireside chat event on Thursday December 7, 2023 beginning at noon Central Time. The event will be hosted by a covering research analyst and feature interactive Q&A with Brent T. Lucas, Chief Executive Officer, and David R. Wells, Chief Financial Officer. Additionally, the Company

    12/4/23 8:15:00 AM ET
    $COCH
    Industrial Specialties
    Health Care

    $COCH
    Financials

    Live finance-specific insights

    View All

    Envoy Medical Reports on Second Quarter 2025 Results

    White Bear Lake, Minnesota--(Newsfile Corp. - July 31, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the second quarter ended June 30, 2025, as well as other subsequent events.Financial and Corporate Highlights for Second Quarter and to date:Strong momentum continues in the pivotal clinical trial of its investigational novel hearing device, the fully implanted Acclaim® cochlear implant.Successful activation of all 10 study participants' fully implanted Acclaim® cochlear implants in the first stage of the Company's pivotal clinical trial. A

    7/31/25 8:00:00 AM ET
    $COCH
    Industrial Specialties
    Health Care

    Envoy Medical Reports on First Quarter 2025 Results

    Company Provides Update on Its Pivotal Clinical Study for Fully Implanted Cochlear ImplantWhite Bear Lake, Minnesota--(Newsfile Corp. - May 1, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the first quarter ended March 31, 2025, as well as other subsequent events.Financial and Corporate Highlights for First Quarter and to date:Secured additional $10 Million in funding to advance Pivotal Clinical Trial. Completed Enrollment of 10 participants in "first stage" of Pivotal Clinical Trial of the fully implanted Acclaim® cochlear implant.Activat

    5/1/25 4:30:00 PM ET
    $COCH
    Industrial Specialties
    Health Care

    Envoy Medical Reports Fourth Quarter and Full Year 2024 Financial Results

    Company Provides Corporate Update that Includes Information on its Progress Enrolling Subjects in its Pivotal Clinical Study for Breakthrough Device, the Fully Implanted Acclaim® Cochlear ImplantWhite Bear Lake, Minnesota--(Newsfile Corp. - March 31, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the fourth quarter and full year ended December 31, 2024, as well as other subsequent events.Brent Lucas, CEO of Envoy Medical commented: "Envoy Medical had a successful 2024 and we are off to a wonderful start in 2025. Obtaining FDA's approval to

    3/31/25 9:15:00 AM ET
    $COCH
    Industrial Specialties
    Health Care